Publicacións nas que colabora con Elisa Luño Fernández (36)

2020

  1. miR-146a rs2431697 identifies myeloproliferative neoplasm patients with higher secondary myelofibrosis progression risk

    Leukemia, Vol. 34, Núm. 10, pp. 2648-2659

2018

  1. Azacitidine improves outcome in higher-risk MDS patients with chromosome 7 abnormalities: a retrospective comparison of GESMD and GFM registries

    British Journal of Haematology, Vol. 181, Núm. 3, pp. 350-359

  2. Characterizing patients with multiple chromosomal aberrations detected by FISH in chronic lymphocytic leukemia

    Leukemia and Lymphoma, Vol. 59, Núm. 3, pp. 633-642

2017

  1. Chronic lymphocytic leukemia with isochromosome 17q: An aggressive subgroup associated with TP53 mutations and complex karyotypes

    Cancer Letters, Vol. 409, pp. 42-48

  2. Clinical and biological significance of isolated Y chromosome loss in myelodysplastic syndromes and chronic myelomonocytic leukemia. A report from the Spanish MDS Group

    Leukemia Research, Vol. 63, pp. 85-89

  3. Enumerating bone marrow blasts from nonerythroid cellularity improves outcome prediction in myelodysplastic syndromes and permits a better definition of the intermediate risk category of the Revised International Prognostic Scoring System (IPSS-R)

    American Journal of Hematology, Vol. 92, Núm. 7, pp. 614-621

  4. Multidimensional assessment of patient condition and mutational analysis in peripheral blood, as tools to improve outcome prediction in myelodysplastic syndromes: A prospective study of the Spanish MDS group

    American Journal of Hematology, Vol. 92, Núm. 9, pp. E534-E541

2016

  1. Considering bone marrow blasts from nonerythroid cellularity improves the prognostic evaluation of myelodysplastic syndromes

    Journal of Clinical Oncology, Vol. 34, Núm. 27, pp. 3284-3292

  2. Erythroleukemia shares biological features and outcome with myelodysplastic syndromes with excess blasts: A rationale for its inclusion into future classifications of myelodysplastic syndromes

    Modern Pathology, Vol. 29, Núm. 12, pp. 1541-1551

  3. Karyotypic complexity rather than chromosome 8 abnormalities aggravates the outcome of chronic lymphocytic leukemia patients with TP53 aberrations

    Oncotarget, Vol. 7, Núm. 49, pp. 80916-80924

  4. Prognostic impact of chromosomal translocations in myelodysplastic syndromes and chronic myelomonocytic leukemia patients. A study by the spanish group of myelodysplastic syndromes

    Genes Chromosomes and Cancer, Vol. 55, Núm. 4, pp. 322-327

  5. Response to erythropoietic-stimulating agents in patients with chronic myelomonocytic leukemia

    European Journal of Haematology, Vol. 97, Núm. 1, pp. 33-38

2015

  1. A low frequency of losses in 11q chromosome is associated with better outcome and lower rate of genomic mutations in patients with chronic lymphocytic leukemia

    PLoS ONE, Vol. 10, Núm. 12

  2. Correlation of myelodysplastic syndromes with i(17)(q10) and TP53 and SETBP1 mutations

    British Journal of Haematology

  3. Use of newer prognostic indices for patients with myelodysplastic syndromes in the low and intermediate-1 risk categories: A population-based study

    The Lancet Haematology, Vol. 2, Núm. 6, pp. e260-e266

2014

  1. Distinction between asymptomatic monoclonal b-cell lymphocytosis with cyclin d1 overexpression and mantle cell lymphoma: From molecular profiling to flow cytometry

    Clinical Cancer Research, Vol. 20, Núm. 4, pp. 1007-1019

  2. Interstitial 13q14 deletions detected in the karyotype and translocations with concomitant deletion at 13q14 in chronic lymphocytic leukemia: Different genetic mechanisms but equivalent poorer clinical outcome

    Genes Chromosomes and Cancer, Vol. 53, Núm. 9, pp. 788-797

  3. Multivariate time-dependent comparison of the impact of lenalidomide in lower-risk myelodysplastic syndromes with chromosome 5q deletion

    British Journal of Haematology, Vol. 166, Núm. 2, pp. 189-201

  4. Role of minimal residual disease and chimerism after reduced-intensity and myeloablative allo-transplantation in acute myeloid leukemia and high-risk myelodysplastic syndrome

    Leukemia Research, Vol. 38, Núm. 5, pp. 551-556

  5. Transfusion dependence development and disease evolution in patients with MDS and del(5q) and without transfusion needs at diagnosis

    Leukemia Research, Vol. 38, Núm. 3, pp. 304-309